Description

Baricitinib Trifluoroacetate is a trifluoroacetate salt form of the active pharmaceutical ingredient Baricitinib, a Janus kinase (JAK) inhibitor. This salt form is critical for enhancing the stability, solubility, and overall manufacturability of the final drug product. It is primarily utilized by pharmaceutical companies and research institutions engaged in the development and production of advanced therapeutics for autoimmune and inflammatory conditions. The compound is supplied to meet the stringent quality requirements of the global pharmaceutical supply chain.

Application

• Active Pharmaceutical Ingredient (API) Intermediate: A key starting material or intermediate in the synthesis of Baricitinib API for final drug formulation.
• Pharmaceutical Research & Development: Used in preclinical and clinical studies to investigate the efficacy and safety of JAK inhibitor therapies.
• Reference Standard: Serves as a high-purity chemical standard for analytical method development, validation, and quality control testing in laboratories.
• Process Chemistry: Employed in scale-up and optimization of synthetic routes for Baricitinib production under GMP conditions.
• Formulation Development: Used in studies to develop stable and bioavailable dosage forms, such as tablets or capsules.

Basic Information

Product Name	Baricitinib Trifluoroacetate
CAS No.	1187594-10-0
Molecular Formula	C20H17F3N6O2 • C2HF3O2
Molecular Weight	554.45 g/mol
Synonyms	Baricitinib TFA Salt; Baricitinib Trifluoroacetic acid salt; (1S,3R,4S)-N-(3-{7H-Pyrrolo[2,3-d]pyrimidin-4-yl}-1H-indazol-5-yl)-3-(ethylsulfonyl)-2-azabicyclo[2.2.1]heptane-2-carboxamide trifluoroacetate; LY3009104 Trifluoroacetate; INCB028050 Trifluoroacetate; Olumiant Intermediate Trifluoroacetate; 2-[1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-5-yl]azetidin-3-yl]acetonitrile Trifluoroacetate
EINECS	Contact for details

Quality Control

Our Baricitinib Trifluoroacetate is manufactured under strict quality management systems to ensure batch-to-batch consistency and high purity suitable for pharmaceutical applications. Each lot undergoes comprehensive analytical testing, including HPLC for assay and impurity profiling, residual solvent analysis, and identification tests. A detailed Certificate of Analysis (COA) is provided with each shipment, confirming compliance with agreed specifications. We support development and commercial needs with material traceable to relevant ICH and pharmacopeial guidelines.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and should be handled in a dry environment to prevent degradation. For long-term storage, consider desiccated conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time matches reference
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single unknown impurity ≤0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Water Content (KF)	≤1.0%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.